Bli medlem
Bli medlem

Du är här


Transposagen Biopharmaceuticals, Inc.: Transposagen announces partnering model for its exclusive patents covering rat models of oncology, autoimmune and inflam

Transposagen's patents cover all genetically engineered rat models with a
broad range of valuable disease model phenotypes. Access to these models and
intellectual property are being offered to drug discovery companies solely
through comprehensive licensing and service partnerships

Lexington, KY, Apr. 20, 2015 (GLOBE NEWSWIRE) -- Transposagen, a world leader
in genome engineering technologies and services, announced the registration
of its trademark OncoRat(TM) by the USPTO, for use with rat models for
oncology in issued patent No. 8,722,964. OncoRat(TM) covers all genetically
engineered rat models with oncology phenotypes, regardless of the method used
to create the rat model (e.g. site-specific nucleases, homologous
recombination, transposon insertion, etc.).

Access to the creation and use of patented genetically engineered rat lines is
being offered solely through comprehensive genome engineering IP licensing
and service partnership agreements. Companies that partner with Transposagen
will also gain access to genome engineering intellectual property including
piggyBac(TM), NextGEN(TM) CRISPR and XTN(TM) TALEN technologies. Transposagen
will also perform services for its partners, including custom genetically
engineered cell lines, animal models as well as gene editing reagent kits.
For more on how it works please visit our Partnering page.

Another issued patent, No. 8,558,055, covers all genetically engineered rat
models with autoimmune or inflammatory diseases. Additional pending patents
include rats with severe combined immune deficiency (SCID), diabetes,
obesity, susceptibility to pain, and phenotypes that are the result of
mutations in drug transporter or drug metabolism genes. The phenotype patents
also cover cells derived from genetically engineered rat models with specific
phenotypes, screening methods, as well as assays and kits for drug discovery

Transposagen is the only company that has freedom to operate with both the
enabling genome engineering technologies and the rat phenotype patents.
Please contact us to discuss your custom partnership for access to full
freedom to operate and genome engineering services.

Jack Crawford M.Sc.
Director, Sales & Marketing
Transposagen Biopharmaceuticals
535 West Second St., Suite 10
Lexington, KY 40508
Cell: 315-351-9115


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Transposagen Biopharmaceuticals, Inc. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.